Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

RNA Test for HPV Helps Stratify Cervical Cancer Risk

  • Cancer Network Staff
January 26, 2015
  • Cervical Cancer, Gynecologic Cancers, Gynecological Oncology
Electron micrograph of a negatively stained HPV

A test for several dangerous strains of high-risk human papillomavirus (HPV) using messenger RNA was shown to be reliable and effective for cervical cancer risk stratification among women with atypical results of a Papanicolaou (Pap) test, according to the results of a new study.

Results from the CLEAR study previously led to US Food and Drug Administration of approval of the Aptima genotype assay (Hologic) in October 2012. “High-risk human papillomavirus testing is now recommended for use with Pap testing for routine cervical cancer screening and for the management of women with atypical squamous cells of undetermined significance Pap results,” wrote study authors led by Damon Getman, PhD, of Hologic (the company also funded the CLEAR trial). This new analysis reflex tested women with a positive Aptima test using a specific HPV 16 18/45 genotype assay (AHPV-GT) for further stratification.

The study included 912 women with atypical squamous cells of undetermined significance on a Pap test, and the AHPV-GT test was performed on those found to be positive for high-risk HPV. Of that total, 893 (97.9%) received a definitive diagnosis with AHPV-GT testing.

In the full cohort, 38.8% were high-risk HPV positive; this rate decreased in ascending age groups, from 57% for those aged 21 to 29 years down to 16.7% in those aged 40 years and older (P < .001 for trend). Among the high-risk HPV-positive women, 32.7% of the younger group were positive on the AHPV-GT assay, compared with 37.1% for 30- to 39-year-olds and 35.6% for those at least 40 years of age. AHPV-GT-positive women in the younger group were more likely to be HPV 16-positive, which is most strongly associated with cervical cancer. Women 30 years or older were more likely to be HPV 18/45-positive.

The risk of subsequent detection of cervical intraepithelial neoplasia grade 2 or more (CIN2+) was highest among HPV 16-positive women, at 37%. The risk was 15.9% for HPV 18/45-positive individuals, 14.3% for other high-risk HPV positives, and only 2.2% for AHPV-GT-negative women. Grade 3 (CIN3) or adenocarcinoma in situ was found in 20.5% of HPV 16-positive women, 9.1% of HPV 18/45-positives, 4.3% of other high-risk HPV-positive individuals, and only 0.7% of HPV-negatives.

“It will be critical to introduce new, more specific biomarkers or algorithms to minimize the harms of screening in… lower risk populations,” the authors wrote. “Second, these results raise the question of whether some of these women, especially younger women who are still intending to have children, might benefit from clinical management involving repeat testing in a year rather than being referred to colposcopy.” They concluded that these results show the AHPV-GT test to be an effective risk stratification method for women with abnormal Pap test results.

Related Articles

  • Unexpected Uterine Cancer: Power Morcellation and Mortality
  • Niraparib for Advanced Ovarian Cancer with HRD+ Status Approved by FDA
  • Role of COX7RP in Endometrial, Breast Cancer Growth
  • Analysis of Cervical Mutations Aids Endometrial Cancer Diagnosis
  • Nivolumab May Induce Promising Efficacy Outcomes in Certain Gynecologic Malignancies

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".